Identification of a dual δ or antagonist/μ or agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 14, 2012, Pages 4869-4872

  Breslin, Henry J ^a   Diamond, Craig J ^a   Kavash, Robert W ^a   Cai, Chaozhong ^a   Dyatkin, Alexey B ^a   Miskowski, Tamara A ^a   Zhang, Sui Po ^a   Wade, Paul R ^a   Hornby, Pamela J ^a   He, Wei ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

IBS d; Irritable Bowel Syndrome; Mixed OR antagonist OR agonist; Opioid receptor

Indexed keywords

DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR ANTAGONIST; DUAL DELTA OPIOID RECEPTOR ANTAGONIST MU OPIOID RECEPTOR AGONIST; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTICLE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IRRITABLE COLON; REACTION ANALYSIS; RECEPTOR AFFINITY; RECEPTOR BINDING; STRUCTURE ANALYSIS;

CLINICAL TRIALS, PHASE II AS TOPIC; DIARRHEA; HUMANS; IRRITABLE BOWEL SYNDROME; MOLECULAR STRUCTURE; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863428605     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2012.05.042     Document Type: Article

References (14)

1. J.V. Aldrich Burger's Medicinal Chemistry and Drug Discovery Therapeutic Agents Vol. 3 1996 John Wiley & Son 321 441 5th ed
2. D.S. Fries W.O. Foye, T.L. Lemke, D.A. Williams, Principles of Medicinal Chemistry 4th ed. 1995 Willimams and Wilkins Baltimore, MD 247 269
3. H.J. Breslin, T.A. Miskowski, H.M. Rafferty, S.V. Coutinho, J.M. Palmer, N.H. Wallace, C.R. Schneider, E.S. Kimball, S.-P. Ahang, J. Li, R.W. Colburn, D.J. Stone, R.P. Martinez, and W. He J. Med. Chem. 47 2004 5009
4. H.J. Breslin, C. Cai, T.A. Miskowski, S.V. Coutinho, S.-P. Zhang, P. Hornby, and W. He Bioorg. Med. Chem. Lett. 16 2006 2505
5. S.D. Bryant, Y. Jinsmaa, S. Salvadori, Y. Okada, and L.H. Lazarus Biopolymers 71 2003 86
6. Complete experimental details for hamster vas deferens tissue assay: A.T. McKnight, A.D. Corbett, M. Marcoli, and H.W. Kosterlitz Neuropharmacology 24 1985 1011
7. P.W. Schiller Life Sci. 86 2010 598
8. P.W. Schiller, G. Weltrowska, I. Berezowska, T.M.-D. Nguyen, B.C. Wilkes, C. Lemieux, and N.N. Chung Biopolymers 51 2000 411
9. N. Dietis, R. Guerrini, G. Calo, S. Salvadori, D.J. Rowbotham, and D.G. Lambert Br. J. Anaesth. 103 2009 38
10. Wade, P.R.; Palmer, J.M.; McKenney, S.; Kenigs, V.; Chevalier, K.; Moore, B.A.; Mabus, J.R.; Saunders, P.; Wallace, N.H.; Schneider, C.R.; Kimball, E.; Breslin, H.J.; He, W.; Hornby, P.J. Br. J. Pharmacol., in press.
11. http://www.absorption.com/site/.
12. Cardiovascular long QT syndrome was assessed by 5l inhibition of [3H]-astemizole binding to the hERG-encoded channel; internal assay as described by P.J. Chiu, K.F. Marcoe, S.E. Bounds, C.H. Lin, J.J. Feng, A. Lin, F.C. Cheng, W.J. Crumb, and R. Mitchell J. Pharmacol. Sci. 95 2004 311
13. 50) by 5l of cytochrome P450 3A4 using 6β-hydroxylation of substrate testosterone in HLM; based on R.W. Wang, D.J. Newton, N. Liu, W.M. Atkins, and A.Y. Lu Drug Metab. Dispos. 28 2000 360
14. Preparation of 13 previously reported: C. Cai, H.J. Breslin, and W. He Tetrahedron 61 2005 6836